-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] According to CDE's public information, Hengrui Medicine's HRS-4642 injection has recently been approved for clinical use in KRAS G12D-mutated advanced solid tumo.
KRAS is one of the most frequently mutated genes in tumo.
When KRAS is mutated, the protein will continue to activate, abnormally activate downstream signaling pathways, and lead to uncontrolled cell growth and tumor formati.
According to Frost & Sullivan data, the global incidence of major KRAS mutation-positive cancers has exceeded 2 million in 2020, reaching 009 million, and is expected to grow to 276 million in 202The vast majority of patients face enormous unmet clinical nee.
In recent years, the research and development boom of KRAS G12C inhibitors has intensified, and the competition has become more inten.
The development of targeting KRAS G12D is seen as the next research fronti.
In China, in addition to Hengrui, there are also pharmaceutical companies such as Ailes and Yifang Biosciences conducting research on KRAS G12D mutation in Chi.
Among them, Hengrui Medicine's KRAS G12D inhibitor HRS-4642 injection has recently been approved for clinical u.
's produc.
With the follow-up clinical advancement, it is believed that it is expected to bring more treatment options and hope to patien.
Hengrui Medicine's R&D investment is increasing year by ye.
In 2021, the company's R&D investment has reached 203 billion yuan, accounting for 295% of sales revenue, which further promotes the company's innovative pipeline product research and developme.
With continuous high R&D investment, the company has received good ne.
During the year, 20 new class 1 drugs have been approved for clinical use, including 9 new class 1 tumor dru.
In addition to HRS-4642 injection, Hengrui's new clinical oncology drugs approved this year include SHR-1802 for injection, adebelimumab injection (including 3 indications), and SHR-A1811 for injection (including 3 indications) 9 drugs, including HRS-1167 tablets, SHR-1501 for injection, e.
The indications mainly involve subdivided therapeutic fields such as advanced solid tumors, non-small cell lung cancer, and breast canc.
Many clinically approved products have great potenti.
For example, SHR-1802, a humanized monoclonal antibody for injection independently developed and produced by Hengrui, can activate and promote anti-tumor T cell responses and play an anti-tumor effe.
After inquiries, there is currently no similar product on the market in China, and there is no relevant sales data; it is also a humanized anti-PD-L1 monoclonal antibody adebelimumab independently developed by the compa.
Blocking the PD-1/PD-L1 pathway that leads to tumor immune tolerance reactivates the anti-tumor activity of the immune system, so as to achieve the purpose of treating tumo.
In China, similar products, including Nvolimumab and Sugeli, have been approved by the State Food and Drug Administrati.
Upon inquiry, the combined global sales of Atezolizumab, Avelumab and Durvalumab in 2021 will be approximately US$7 billi.
However, there are also products with more intense competition on the tra.
For example, SHR-A1811 for injection can bind to and endocytose HER2-expressing tumor cells, release toxins through proteolytic cleavage in tumor cell lysosomes, induce cell cycle arrest and induce tumor cell apoptos.
At present, similar products that have been listed abroad include Roche's Kadcyla), AstraZeneca and Daiichi Sankyo jointly developed Enher.
In addition, there are ARX788, DP303c, A166, RC48, SYD985, BAT8001 and other products in clinical trials at home and abro.
After querying the Evaluatepharma database, the combined global sales of Kadcyla and Enhertu in 2021 will be approximately US$752 billi.
The number of cancer patients in China is hu.
With the upgrade of residents' consumption level and the advancement of medical technology, the market size of anti-tumor drugs has also continued to expa.
Some data predict that the market size of China's anti-tumor drugs may reach 412 billion yuan in 2025, and by 2030 this figure will reach 681 billion yu.
In the face of a considerable market, and drug innovation is being supported by a series of favorable policies, the enthusiasm of pharmaceutical companies for innovation continues to rise, and anti-tumor drugs have also become the current hot spot for new drug research and developme.
It is understood that in the first half of this year alone, 15 oncology drugs have been approved for marketing in China, involving gastric cancer, bile duct cancer, cervical cancer, lung cancer, Hodgkin lymphoma, leukemia, prostate cancer,e.
It is foreseeable that with the efforts of many pharmaceutical companies, cancer patients will usher in more treatment options in the futu.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
KRAS is one of the most frequently mutated genes in tumo.
When KRAS is mutated, the protein will continue to activate, abnormally activate downstream signaling pathways, and lead to uncontrolled cell growth and tumor formati.
According to Frost & Sullivan data, the global incidence of major KRAS mutation-positive cancers has exceeded 2 million in 2020, reaching 009 million, and is expected to grow to 276 million in 202The vast majority of patients face enormous unmet clinical nee.
In recent years, the research and development boom of KRAS G12C inhibitors has intensified, and the competition has become more inten.
The development of targeting KRAS G12D is seen as the next research fronti.
In China, in addition to Hengrui, there are also pharmaceutical companies such as Ailes and Yifang Biosciences conducting research on KRAS G12D mutation in Chi.
Among them, Hengrui Medicine's KRAS G12D inhibitor HRS-4642 injection has recently been approved for clinical u.
's produc.
With the follow-up clinical advancement, it is believed that it is expected to bring more treatment options and hope to patien.
Hengrui Medicine's R&D investment is increasing year by ye.
In 2021, the company's R&D investment has reached 203 billion yuan, accounting for 295% of sales revenue, which further promotes the company's innovative pipeline product research and developme.
With continuous high R&D investment, the company has received good ne.
During the year, 20 new class 1 drugs have been approved for clinical use, including 9 new class 1 tumor dru.
In addition to HRS-4642 injection, Hengrui's new clinical oncology drugs approved this year include SHR-1802 for injection, adebelimumab injection (including 3 indications), and SHR-A1811 for injection (including 3 indications) 9 drugs, including HRS-1167 tablets, SHR-1501 for injection, e.
The indications mainly involve subdivided therapeutic fields such as advanced solid tumors, non-small cell lung cancer, and breast canc.
Many clinically approved products have great potenti.
For example, SHR-1802, a humanized monoclonal antibody for injection independently developed and produced by Hengrui, can activate and promote anti-tumor T cell responses and play an anti-tumor effe.
After inquiries, there is currently no similar product on the market in China, and there is no relevant sales data; it is also a humanized anti-PD-L1 monoclonal antibody adebelimumab independently developed by the compa.
Blocking the PD-1/PD-L1 pathway that leads to tumor immune tolerance reactivates the anti-tumor activity of the immune system, so as to achieve the purpose of treating tumo.
In China, similar products, including Nvolimumab and Sugeli, have been approved by the State Food and Drug Administrati.
Upon inquiry, the combined global sales of Atezolizumab, Avelumab and Durvalumab in 2021 will be approximately US$7 billi.
However, there are also products with more intense competition on the tra.
For example, SHR-A1811 for injection can bind to and endocytose HER2-expressing tumor cells, release toxins through proteolytic cleavage in tumor cell lysosomes, induce cell cycle arrest and induce tumor cell apoptos.
At present, similar products that have been listed abroad include Roche's Kadcyla), AstraZeneca and Daiichi Sankyo jointly developed Enher.
In addition, there are ARX788, DP303c, A166, RC48, SYD985, BAT8001 and other products in clinical trials at home and abro.
After querying the Evaluatepharma database, the combined global sales of Kadcyla and Enhertu in 2021 will be approximately US$752 billi.
The number of cancer patients in China is hu.
With the upgrade of residents' consumption level and the advancement of medical technology, the market size of anti-tumor drugs has also continued to expa.
Some data predict that the market size of China's anti-tumor drugs may reach 412 billion yuan in 2025, and by 2030 this figure will reach 681 billion yu.
In the face of a considerable market, and drug innovation is being supported by a series of favorable policies, the enthusiasm of pharmaceutical companies for innovation continues to rise, and anti-tumor drugs have also become the current hot spot for new drug research and developme.
It is understood that in the first half of this year alone, 15 oncology drugs have been approved for marketing in China, involving gastric cancer, bile duct cancer, cervical cancer, lung cancer, Hodgkin lymphoma, leukemia, prostate cancer,e.
It is foreseeable that with the efforts of many pharmaceutical companies, cancer patients will usher in more treatment options in the futu.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
